Literature DB >> 3662470

Pharmacokinetics and tissue penetration of roxithromycin after multiple dosing.

R Wise1, B Kirkpatrick, J Ashby, J M Andrews.   

Abstract

The pharmacokinetics of the macrolide roxithromycin (RU 28965) were studied during and after administration of 150 mg every 12 h for 3 days (five doses) in six volunteers. The concentrations in serum, blister fluid, and urine were measured. Mean levels in serum taken at 1.5 h after the morning dose increased from 4.4 micrograms/ml on day 1 to 5.9 micrograms/ml on day 2 and 7.4 micrograms/ml on day 3. The mean serum and blister fluid elimination half-lives on day 3 were 13.2 and 12.5 h, respectively. Roxithromycin penetrated blister fluid well; the mean percent penetration (as measured by the ratio of areas under the curve) was 85%. After the final dose, a mean of 10.5% of that dose was recovered in 12 h as microbiologically active compound.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3662470      PMCID: PMC174870          DOI: 10.1128/AAC.31.7.1051

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

3.  [RU 28965, a new semi-synthetic macrolide. Bioavailability and pharmacokinetic profile after oral administration].

Authors:  D Tremblay; A Bryskier; M Vuckovic; A Stockis; C Manuel
Journal:  Pathol Biol (Paris)       Date:  1985-06

4.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

5.  In vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) against clinical isolates of Haemophilus influenzae.

Authors:  J H Jorgensen; J S Redding; A W Howell
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

  5 in total
  10 in total

1.  Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption.

Authors:  M Boeckh; H Lode; G Höffken; S Daeschlein; P Koeppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

3.  Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice.

Authors:  R H Gelber; P Siu; M Tsang; L P Murray
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

4.  Concentrations of roxithromycin (RU 28965) in serum and in sinus mucosa.

Authors:  A Kropec; E Schmidt-Eisenlohr; F D Daschner
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

5.  Roxithromycin disposition in tonsils after single and repeated administrations.

Authors:  G B Galioto; G Ortisi; E Mevio; D Sassella; F Bartucci; G Privitera
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding.

Authors:  Michael J Dolton; David Z D'Argenio
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

Review 7.  Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.

Authors:  Vincent J Venditto; David J Feola
Journal:  Adv Drug Deliv Rev       Date:  2022-03-30       Impact factor: 17.873

8.  Disposition of roxithromycin in patients with normal and severely impaired renal function.

Authors:  C E Halstenson; J A Opsahl; M H Schwenk; J M Kovarik; S K Puri; I Ho; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 9.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

Review 10.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.